NASDAQ: ACET · Life Sciences · 4 alerts · CIK 1720580
Share price
$2.75Close, Nov 16
Market cap
$25.7M
Shares outstanding
9.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adicet Bio, Inc. filings on SEC EDGAR ↗
Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.
Adicet Bio reported third quarter 2026 financial results and provided updates on its clinical pipeline, including positive Phase 1 data for prula-cel in systemic lupus erythematosus. The company ended the quarter with $204.4 million in cash and cash equivalents, providing a projected runway into the second half of 2027.
Term
Q3 2026
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”
Chen Schor, President and Chief Executive Officer of Adicet Bio
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, with its lead candidate prula-cel (ADI-001) currently in Phase 1 trials. The company reported 9,361,596 shares of common stock outstanding as of November 3, 2026, and highlighted significant risks including the need for substantial additional financing and reliance on third-party manufacturing.